| Literature DB >> 28552348 |
Abigail E Overacre-Delgoffe1, Maria Chikina2, Rebekah E Dadey3, Hiroshi Yano3, Erin A Brunazzi3, Gulidanna Shayan4, William Horne5, Jessica M Moskovitz6, Jay K Kolls7, Cindy Sander8, Yongli Shuai9, Daniel P Normolle9, John M Kirkwood10, Robert L Ferris11, Greg M Delgoffe12, Tullia C Bruno13, Creg J Workman1, Dario A A Vignali14.
Abstract
Regulatory T cells (Tregs) are a barrier to anti-tumor immunity. Neuropilin-1 (Nrp1) is required to maintain intratumoral Treg stability and function but is dispensable for peripheral immune tolerance. Treg-restricted Nrp1 deletion results in profound tumor resistance due to Treg functional fragility. Thus, identifying the basis for Nrp1 dependency and the key drivers of Treg fragility could help to improve immunotherapy for human cancer. We show that a high percentage of intratumoral NRP1+ Tregs correlates with poor prognosis in melanoma and head and neck squamous cell carcinoma. Using a mouse model of melanoma where Nrp1-deficient (Nrp1-/-) and wild-type (Nrp1+/+) Tregs can be assessed in a competitive environment, we find that a high proportion of intratumoral Nrp1-/- Tregs produce interferon-γ (IFNγ), which drives the fragility of surrounding wild-type Tregs, boosts anti-tumor immunity, and facilitates tumor clearance. We also show that IFNγ-induced Treg fragility is required for response to anti-PD1, suggesting that cancer therapies promoting Treg fragility may be efficacious.Entities:
Keywords: PD-1; cancer immunotherapy; interferon-γ; interferon-γ receptor; neuropilin-1; regulatory T cells; tumor immunology; tumor microenvironment
Mesh:
Substances:
Year: 2017 PMID: 28552348 PMCID: PMC5509332 DOI: 10.1016/j.cell.2017.05.005
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582